Fresenius Medical Care AG & Co. KGAA proposed a 5% higher dividend of EUR 0.63 per preference one for the full year of 2009.

Fresenius Medical Care AG & Co. KGAA reported consolidated earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, the company has reported EBIT of $490,792,000, EBITDA of $613,744,000, income before taxes of $415,498,000 and net income attributable to company of $246,619,000 or $0.82 per ordinary share ADS on total net revenue of $3,035,429,000 compared to EBIT of $432,526,000, EBITDA of $541,436,000, income before taxes of $347,793,000 and net income attributable to company of $214,311,000 or $0.72 per ordinary share ADS on total net revenue of $2,722,038,000 for the same period last year. For the year, the company has reported EBIT of $1,755,596,000, EBITDA of $2,212,681,000, income before taxes of $1,455,633,000 and net income attributable to company of $891,138,000 or $2.99 per ordinary share ADS on total net revenue of $11,247,477,000 compared to EBIT of $1,672,432,000, EBITDA of $2,088,103,000, income before taxes of $1,335,690,000 and net income attributable to company of $817,607,000 or $2.75 per ordinary share ADS on total net revenue of $10,612,323,000 for the same period last year. Cash flow from operating activities was $1.339 million against $1.016 million and expenditure on purchase of property, plant and equipment was $574 million against $687 million reported last year. The company will continue to follow an earnings-driven dividend policy. For the 13th consecutive year, shareholders can expect to receive an increased annual dividend for the fiscal year 2009. At the Annual General Meeting to be held on May 11, 2010, shareholders will be asked to approve a dividend of EUR 0.61 per ordinary share, an increase of 5% from EUR 0.58 declared in 2008. For the full year of 2010, the company expects to achieve revenue of more than $12 billion. Net income attributable to FMC AG & Co. KGaA is expected to be between $950 and $980 million in 2010. The Company expects to spend $550 to $650 million on capital expenditures and up to $400 million on acquisitions. The debt/EBITDA ratio is expected to be below 2.5 by the end of 2010. Rice Powell has been appointed Deputy Chairman of the Fresenius Medical Care Management Board. The Company has also appointed Mike Brosnan as Chief Financial Officer. Kent Wanzek was named to the new Fresenius Medical Care Management Board position for Global Manufacturing Operations to provide stronger manufacturing coordination on a global basis.

Fresenius Medical Care AG & Co. KGAA, Q4 2009 Earnings Call, Feb-24-2010